JOP20200022A1 - مركبات حلقية لولبية وطرق تصنيعها واستخدامها - Google Patents
مركبات حلقية لولبية وطرق تصنيعها واستخدامهاInfo
- Publication number
- JOP20200022A1 JOP20200022A1 JOP/2020/0022A JOP20200022A JOP20200022A1 JO P20200022 A1 JOP20200022 A1 JO P20200022A1 JO P20200022 A JOP20200022 A JO P20200022A JO P20200022 A1 JOP20200022 A1 JO P20200022A1
- Authority
- JO
- Jordan
- Prior art keywords
- making
- methods
- same
- compounds
- spirocycle
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 abstract 2
- 102100029814 Monoglyceride lipase Human genes 0.000 abstract 1
- 101710116393 Monoglyceride lipase Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/56—Nitrogen atoms
- C07D211/58—Nitrogen atoms attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762551714P | 2017-08-29 | 2017-08-29 | |
| PCT/US2018/048388 WO2019046330A1 (en) | 2017-08-29 | 2018-08-28 | SPIROCYCLIC COMPOUNDS AND METHODS OF PREPARATION AND USE THEREOF |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JOP20200022A1 true JOP20200022A1 (ar) | 2020-02-02 |
Family
ID=65526036
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JOP/2020/0022A JOP20200022A1 (ar) | 2017-08-29 | 2018-08-28 | مركبات حلقية لولبية وطرق تصنيعها واستخدامها |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US11161856B2 (OSRAM) |
| EP (1) | EP3675848B1 (OSRAM) |
| JP (1) | JP7177825B2 (OSRAM) |
| KR (1) | KR20200046053A (OSRAM) |
| CN (1) | CN111032034B (OSRAM) |
| AU (1) | AU2018326497A1 (OSRAM) |
| BR (1) | BR112020003946A2 (OSRAM) |
| CA (1) | CA3072926A1 (OSRAM) |
| CL (1) | CL2020000463A1 (OSRAM) |
| CO (1) | CO2020001715A2 (OSRAM) |
| CR (1) | CR20200088A (OSRAM) |
| DO (1) | DOP2020000040A (OSRAM) |
| EA (1) | EA202090296A1 (OSRAM) |
| EC (1) | ECSP20013332A (OSRAM) |
| ES (1) | ES2914363T3 (OSRAM) |
| IL (1) | IL272578A (OSRAM) |
| JO (1) | JOP20200022A1 (OSRAM) |
| MA (1) | MA50045A (OSRAM) |
| MX (1) | MX2020002254A (OSRAM) |
| PE (1) | PE20200665A1 (OSRAM) |
| PH (1) | PH12020500371A1 (OSRAM) |
| RU (1) | RU2020107039A (OSRAM) |
| SG (1) | SG11202000984YA (OSRAM) |
| WO (1) | WO2019046330A1 (OSRAM) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ627750A (en) | 2012-01-06 | 2016-11-25 | Abide Therapeutics Inc | Carbamate compounds and of making and using same |
| CN109496213B (zh) | 2016-05-12 | 2022-03-04 | H.隆德贝克有限公司 | 螺环化合物及其制备和使用方法 |
| US10899737B2 (en) | 2016-09-19 | 2021-01-26 | Lundbeck La Jolla Research Center, Inc. | Piperazine carbamates and methods of making and using same |
| JOP20190107A1 (ar) | 2016-11-16 | 2019-05-09 | Lundbeck La Jolla Research Center Inc | مثبطات أحادي أسيل جليسرول ليباز (magl) |
| BR112020003946A2 (pt) | 2017-08-29 | 2020-09-08 | Lundbeck La Jolla Research Center, Inc. | compostos de espirociclo e métodos para produzir e usar os mesmos |
| ES2952332T3 (es) | 2017-08-29 | 2023-10-30 | H Lundbeck As | Compuestos espirocíclicos y sus métodos de preparación y uso |
| KR20210010475A (ko) | 2018-05-15 | 2021-01-27 | 룬드벡 라 졸라 리서치 센터 인코포레이티드 | Magl 저해제 |
| CN111505410B (zh) * | 2020-04-02 | 2022-07-29 | 矽力杰半导体技术(杭州)有限公司 | 调光模式检测电路、方法和无调光检测电路及照明系统 |
| KR20230004622A (ko) | 2020-04-21 | 2023-01-06 | 하. 룬드벡 아크티에셀스카브 | 모노아실글리세롤 리파제 억제제의 합성 |
| US11434222B2 (en) * | 2020-11-13 | 2022-09-06 | H. Lundbeck A/S | MAGL inhibitors |
| WO2022165513A1 (en) | 2021-01-29 | 2022-08-04 | Cedilla Therapeutics, Inc. | Cdk2 inhibitors and methods of using the same |
| US12053459B2 (en) | 2021-06-26 | 2024-08-06 | Cedilla Therapeutics, Inc. | CDK2 inhibitors and methods of using the same |
| US20250084065A1 (en) | 2021-12-29 | 2025-03-13 | Psy Therapeutics, Inc. | Inhibiting monoacylglycerol lipase (magl) |
| CN119137114A (zh) | 2022-05-04 | 2024-12-13 | H.隆德贝克有限公司 | 作为单酰基甘油脂肪酶抑制剂的(s)-1-(哒嗪-3-基氨基甲酰基)-6-氮杂螺[2.5]辛烷-6-甲酸1,1,1,3,3,3-六氟丙-2-酯的结晶形式 |
| WO2024168426A1 (en) | 2023-02-13 | 2024-08-22 | Apogee Pharmaceuticals, Inc. | Small molecules as monoacylglycerol lipase (magl) inhibitors, compositions and use thereof |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002070523A1 (en) | 2001-03-07 | 2002-09-12 | Pfizer Products Inc. | Modulators of chemokine receptor activity |
| EP2065369A4 (en) * | 2006-08-23 | 2011-12-28 | Astellas Pharma Inc | UREA CONNECTION OR SALT THEREOF |
| AU2009221860A1 (en) | 2008-03-05 | 2009-09-11 | Targacept, Inc. | Nicotinic acetylcholine receptor sub-type selective amides of diazabicycloal kanes |
| US20120083476A1 (en) | 2009-06-05 | 2012-04-05 | Janssen Pharmaceutica Nv | Heteroaryl-substituted spirocyclic diamine urea modulators of fatty acid amide hydrolase |
| HUE043962T2 (hu) | 2009-10-23 | 2019-09-30 | Janssen Pharmaceutica Nv | Diszubsztituált oktahidro-pirrolo[3,4-C]pirrolok mint orexin receptor modulátorok |
| CA2791672A1 (en) | 2010-03-04 | 2011-09-09 | Merck Sharp & Dohme Corp. | Positive allosteric modulators of mglur2 |
| FR2960875B1 (fr) | 2010-06-04 | 2012-12-28 | Sanofi Aventis | Derives de carbamates d'hexafluoroisopropyle, leur preparation et leur application en therapeutique |
| EP2444084A1 (en) | 2010-10-21 | 2012-04-25 | Centro Nacional de Investigaciones Oncológicas (CNIO) | Use of PI3K inibitors for the treatment of obesity |
| NZ627750A (en) * | 2012-01-06 | 2016-11-25 | Abide Therapeutics Inc | Carbamate compounds and of making and using same |
| HRP20191937T1 (hr) | 2012-09-25 | 2020-01-10 | F. Hoffmann - La Roche Ag | Derivati heksahidropirolo [3,4-c]pirola i srodni spojevi kao inhibitori autotaksina (atx) i kao inhibitori proizvodnje lizofosfatidne kiseline (lpa) za liječenje npr. bubrežnih bolesti |
| US9828379B2 (en) | 2013-07-03 | 2017-11-28 | Abide Therapeutics, Inc. | Pyrrolo-pyrrole carbamate and related organic compounds, pharmaceutical compositions, and medical uses thereof |
| WO2016149401A2 (en) * | 2015-03-18 | 2016-09-22 | Abide Therapeutics, Inc. | Piperazine carbamates and methods of making and using same |
| WO2017021805A1 (en) | 2015-07-31 | 2017-02-09 | Pfizer Inc. | 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2-yl carbamate derivatives as magl inhibitors |
| US10519134B2 (en) * | 2015-11-20 | 2019-12-31 | Lundbeck La Jolla Research Center, Inc. | Pyrazole compounds and methods of making and using same |
| CN109496213B (zh) | 2016-05-12 | 2022-03-04 | H.隆德贝克有限公司 | 螺环化合物及其制备和使用方法 |
| JOP20190107A1 (ar) | 2016-11-16 | 2019-05-09 | Lundbeck La Jolla Research Center Inc | مثبطات أحادي أسيل جليسرول ليباز (magl) |
| BR112020003946A2 (pt) | 2017-08-29 | 2020-09-08 | Lundbeck La Jolla Research Center, Inc. | compostos de espirociclo e métodos para produzir e usar os mesmos |
| ES2952332T3 (es) | 2017-08-29 | 2023-10-30 | H Lundbeck As | Compuestos espirocíclicos y sus métodos de preparación y uso |
-
2018
- 2018-08-28 BR BR112020003946-2A patent/BR112020003946A2/pt not_active Application Discontinuation
- 2018-08-28 JO JOP/2020/0022A patent/JOP20200022A1/ar unknown
- 2018-08-28 CR CR20200088A patent/CR20200088A/es unknown
- 2018-08-28 JP JP2020512612A patent/JP7177825B2/ja active Active
- 2018-08-28 US US16/642,713 patent/US11161856B2/en active Active
- 2018-08-28 CN CN201880054296.1A patent/CN111032034B/zh active Active
- 2018-08-28 EA EA202090296A patent/EA202090296A1/ru unknown
- 2018-08-28 SG SG11202000984YA patent/SG11202000984YA/en unknown
- 2018-08-28 MX MX2020002254A patent/MX2020002254A/es unknown
- 2018-08-28 WO PCT/US2018/048388 patent/WO2019046330A1/en not_active Ceased
- 2018-08-28 ES ES18852217T patent/ES2914363T3/es active Active
- 2018-08-28 PE PE2020000297A patent/PE20200665A1/es unknown
- 2018-08-28 RU RU2020107039A patent/RU2020107039A/ru unknown
- 2018-08-28 KR KR1020207007712A patent/KR20200046053A/ko not_active Withdrawn
- 2018-08-28 CA CA3072926A patent/CA3072926A1/en not_active Abandoned
- 2018-08-28 EP EP18852217.1A patent/EP3675848B1/en active Active
- 2018-08-28 MA MA050045A patent/MA50045A/fr unknown
- 2018-08-28 AU AU2018326497A patent/AU2018326497A1/en not_active Abandoned
-
2020
- 2020-02-10 IL IL272578A patent/IL272578A/en unknown
- 2020-02-14 CO CONC2020/0001715A patent/CO2020001715A2/es unknown
- 2020-02-21 EC ECSENADI202013332A patent/ECSP20013332A/es unknown
- 2020-02-21 DO DO2020000040A patent/DOP2020000040A/es unknown
- 2020-02-24 PH PH12020500371A patent/PH12020500371A1/en unknown
- 2020-02-25 CL CL2020000463A patent/CL2020000463A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3675848B1 (en) | 2022-03-23 |
| ECSP20013332A (es) | 2020-04-22 |
| CN111032034B (zh) | 2023-05-02 |
| JP7177825B2 (ja) | 2022-11-24 |
| US11161856B2 (en) | 2021-11-02 |
| EA202090296A1 (ru) | 2020-08-03 |
| MX2020002254A (es) | 2020-07-20 |
| CA3072926A1 (en) | 2019-03-07 |
| KR20200046053A (ko) | 2020-05-06 |
| RU2020107039A (ru) | 2021-09-30 |
| CO2020001715A2 (es) | 2020-02-28 |
| ES2914363T3 (es) | 2022-06-09 |
| PH12020500371A1 (en) | 2020-12-07 |
| US20210214375A1 (en) | 2021-07-15 |
| JP2020532547A (ja) | 2020-11-12 |
| EP3675848A1 (en) | 2020-07-08 |
| PE20200665A1 (es) | 2020-06-11 |
| CN111032034A (zh) | 2020-04-17 |
| EP3675848A4 (en) | 2021-03-10 |
| CR20200088A (es) | 2020-04-08 |
| WO2019046330A1 (en) | 2019-03-07 |
| MA50045A (fr) | 2020-07-08 |
| BR112020003946A2 (pt) | 2020-09-08 |
| IL272578A (en) | 2020-03-31 |
| CL2020000463A1 (es) | 2020-07-10 |
| DOP2020000040A (es) | 2020-08-31 |
| AU2018326497A1 (en) | 2020-02-20 |
| SG11202000984YA (en) | 2020-03-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12020500371A1 (en) | Spirocycle compounds and methods of making and using same | |
| PH12020500372A1 (en) | Spirocycle compounds and methods of making and using same | |
| MX2017011997A (es) | Carbamatos de piperacina y metodos de preparacion y uso. | |
| MX2020012797A (es) | Anticuerpos biespecificos anti-pvrig/anti-tigit y métodos de uso. | |
| PH12019502646A1 (en) | Pyrazole magl inhibitors | |
| PH12019501079A1 (en) | Magl inhibitors | |
| ZA201906111B (en) | Cyclic di-nucleotides compounds for the treatment of cancer | |
| PH12019501097A1 (en) | Magl inhibitors | |
| GEP20247593B (en) | Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders | |
| PH12019501102A1 (en) | Magl inhibitors | |
| GB2541571A (en) | Pharmaceutical compositions | |
| EA201891200A1 (ru) | Композиции, содержащие бактериальные штаммы | |
| WO2015179559A3 (en) | Pyrazole compounds and methods of making and using same | |
| MX2017006694A (es) | Compuestos biciclicos fusionados para el tratamiento de enfermedades. | |
| MX2018004674A (es) | Moduladores de interacción de sestrina-gator2 y sus usos. | |
| EP4417262A3 (en) | Combination therapy | |
| AU2018253600A1 (en) | Dosage forms and therapeutic uses of l-4-chlorokynurenine | |
| MX2020008195A (es) | Compuestos para el tratamiento del dolor. | |
| MX2020012990A (es) | Formulaciones de tegavivint y compuestos relacionados. | |
| MX382092B (es) | Compuestos heterocíclicos para el tratamiento de enfermedades. | |
| MY178960A (en) | Hiv treatment formulation of atazanavir and cobicistat | |
| MX370897B (es) | Compuestos bicíclicos fusionados para el tratamiento de enfermedades, | |
| MX2018014034A (es) | Compuestos bicíclicos fusionados para el tratamiento de enfermedades. | |
| MX2019014475A (es) | Formulaciones de lixivaptan para el tratamiento de enfermedades poliquisticas. | |
| NZ750581A (en) | Compositions and methods for treating neurodegenerative diseases and cardiomyopathy |